Cardiff Oncology share price today

(CRDF)

Cardiff Oncology share price is $4.26 & ₹365.25 as on 3 Jan 2025, 2.30 'hrs' IST

$4.26

▲

-0.08

(-1.84%)

Market is closed - opens 8 PM, 03 Jan 2025

View live Cardiff Oncology share price in Dollar and Rupees. Guide to invest in Cardiff Oncology from India. Also see the sentimental analysis on Indian investors investing in Cardiff Oncology. Get details on the Indian mutual funds that are investing in Cardiff Oncology. Get Analyst recommendations and forecasts along with all the Cardiff Oncology's financials.

Cardiff Oncology share price movements

Today's Low: $4.24
Today's High: $4.63
$4.26
0.47%
Downside
Day's Volatility :8.42%
Upside
7.99%
52 Weeks Low: $1.44
52 Weeks High: $6.42
$4.26
66.2%
Downside
52 Weeks Volatility :77.57%
Upside
33.64%

Cardiff Oncology Returns

Period	Cardiff Oncology Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	66.92%	-10.0%	0.0%
6 Months	96.38%	-4.7%	0.0%
1 Year	161.45%	-0.9%	0.0%
3 Years	-31.0%	-2.4%	-21.2%

Cardiff Oncology Key Statistics

in dollars & INR

Previous Close	$4.34
Open	$4.4
Today's High	$4.63
Today's Low	$4.24
Market Capitalization	$288.7M
Today's Volume	$886.5K
52 Week High	$6.42
52 Week Low	$1.44
Revenue TTM	$688.0K
EBITDA	$-46.0M
Earnings Per Share (EPS)	$-0.95
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-67.57%

How to invest in Cardiff Oncology from India?

It is very easy for Indian residents to invest directly in Cardiff Oncology from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cardiff Oncology stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cardiff Oncology or CRDF on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cardiff Oncology or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cardiff Oncology shares which would translate to 0.201 fractional shares of Cardiff Oncology as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cardiff Oncology, in just a few clicks!

Returns in Cardiff Oncology for Indian investors in Rupees

Investment Value

₹1,00,000

Cardiff Oncology investment value today

Current value as on today

₹2,59,601

Returns

₹1,59,601

(+159.6%)

Returns from Cardiff Oncology Stock

₹1,56,627 (+156.63%)

Dollar Returns

₹2,975 (+2.97%)

Indian investors sentiment towards Cardiff Oncology

310.0%

Period: Oct 4, 2024 to Jan 2, 2025. Change in 30 Days versus previous period

Investment in Cardiff Oncology from India has grown in the last 30 days as on Jan 3, 2025. 310.0% more purchase transactions for Cardiff Oncology in the last 30 days versus the previous period.

109%

Period: Oct 4, 2024 to Jan 2, 2025. Change in 30 Days versus previous period

Search volume for Cardiff Oncology on INDmoney from India has grown in the last 30 days as on Jan 3, 2025. 109% more investors are searching Cardiff Oncology in the last 30 days versus the previous period.

Global Institutional Holdings in Cardiff Oncology

BlackRock Inc
5.14%
Vanguard Group Inc
4.25%
Geode Capital Management, LLC
1.82%
State Street Corp
1.63%
Mccormack Advisors International
1.30%
Renaissance Technologies Corp
1.18%

Analyst Recommendation on Cardiff Oncology

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Cardiff Oncology(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cardiff Oncology

What analysts predicted

Upside of 152.35%

Current:

$4.26

Target:

$10.75

Insights on Cardiff Oncology

Price Movement
In the last 1 month, CRDF stock has moved up by 63.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 163.0K → 165.0K (in $), with an average increase of 1.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -9.33M → -11.85M (in $), with an average decrease of 8.5% per quarter
CRDF vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 66.6%

Cardiff Oncology Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$378.0K	↓ 25.15%
Net Income	$-16.5M	↓ 33.91%
Net Profit Margin	-4.4K%	↑ 577.32%

	FY19	Y/Y Change
Revenue	$245.0K	↓ 35.19%
Net Income	$-16.2M	↓ 1.88%
Net Profit Margin	-6.6K%	↓ 2237.89%

	FY20	Y/Y Change
Revenue	$366.0K	↑ 49.38%
Net Income	$-19.3M	↑ 19.37%
Net Profit Margin	-5.3K%	↑ 1324.8%

	FY21	Y/Y Change
Revenue	$359.0K	↓ 1.91%
Net Income	$-27.7M	↑ 43.89%
Net Profit Margin	-7.7K%	↓ 2459.73%

	FY22	Y/Y Change
Revenue	$386.0K	↑ 7.52%
Net Income	$-37.5M	↑ 35.2%
Net Profit Margin	-9.7K%	↓ 1989.0%

	FY23	Y/Y Change
Revenue	$488.0K	↑ 26.42%
Net Income	$-41.4M	↑ 10.49%
Net Profit Margin	-8.5K%	↑ 1224.57%

	Q2 FY23	Q/Q Change
Revenue	$108.0K	↑ 30.12%
Net Income	$-11.2M	↑ 7.27%
Net Profit Margin	-10.3K%	↑ 2198.82%

	Q3 FY23	Q/Q Change
Revenue	$141.0K	↑ 30.56%
Net Income	$-9.7M	↓ 12.73%
Net Profit Margin	-6.9K%	↑ 3422.65%

	Q4 FY23	Q/Q Change
Revenue	$156.0K	↑ 10.64%
Net Income	$-9.3M	↓ 4.05%
Net Profit Margin	-6.0K%	↑ 916.16%

	Q1 FY24	Q/Q Change
Revenue	$205.0K	↑ 31.41%
Net Income	$-10.0M	↑ 7.22%
Net Profit Margin	-4.9K%	↑ 1101.85%

	Q2 FY24	Q/Q Change
Revenue	$163.0K	↓ 20.49%
Net Income	$-11.8M	↑ 17.65%
Net Profit Margin	-7.2K%	↓ 2342.36%

	Q3 FY24	Q/Q Change
Revenue	$165.0K	↑ 1.23%
Net Income	$-11.9M	↑ 0.65%
Net Profit Margin	-7.2K%	↑ 40.92%

	FY18	Y/Y Change
Profit	$-219.0K	↓ 83.23%

	FY19	Y/Y Change
Profit	$-10.9M	↑ 4885.04%

	FY20	Y/Y Change
Profit	$-10.9M	↓ 0.44%

	FY21	Y/Y Change
Profit	$-141.0K	↓ 98.7%

	FY22	Y/Y Change
Profit	$186.0K	↓ 231.91%

	FY23	Y/Y Change
Profit	$488.0K	↑ 162.37%

	Q2 FY23	Q/Q Change
Profit	$10.0K	↓ 242.86%

	Q3 FY23	Q/Q Change
Profit	$34.0K	↑ 240.0%

	Q4 FY23	Q/Q Change
Profit	$53.0K	↑ 55.88%

	Q1 FY24	Q/Q Change
Profit	$103.0K	↑ 94.34%

	Q2 FY24	Q/Q Change
Profit	$58.0K	↓ 43.69%

	Q3 FY24	Q/Q Change
Profit	$165.0K	↑ 184.48%

	FY18	Y/Y Change
Operating Cash Flow	$-13.2M	↓ 43.3%
Investing Cash Flow	$22.8K	↓ 99.9%
Financing Cash Flow	$16.4M	↓ 357.19%

	FY19	Y/Y Change
Operating Cash Flow	$-13.3M	↑ 0.52%
Investing Cash Flow	$-67.6K	↓ 396.04%
Financing Cash Flow	$12.1M	↓ 26.37%

	FY20	Y/Y Change
Operating Cash Flow	$-16.3M	↑ 22.96%
Investing Cash Flow	$-211.9K	↑ 213.33%
Financing Cash Flow	$137.3M	↑ 1036.88%

	FY21	Y/Y Change
Operating Cash Flow	$-23.0M	↑ 41.22%
Investing Cash Flow	$-131.4M	↑ 61938.89%
Financing Cash Flow	$35.5M	↓ 74.18%

	FY22	Y/Y Change
Operating Cash Flow	$-33.8M	↑ 46.79%
Investing Cash Flow	$38.1M	↓ 129.02%
Financing Cash Flow	$75.0K	↓ 99.79%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-7.1M	↓ 17.63%
Investing Cash Flow	$11.5M	↑ 56.69%
Financing Cash Flow	$-6.0K	-

Cardiff Oncology Technicals Summary

Sell

Neutral

Buy

Cardiff Oncology is currently in a neutral trading position according to technical analysis indicators.

Cardiff Oncology Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cardiff Oncology Inc	80.08%	96.38%	161.45%	-31.0%	258.68%
Regeneron Pharmaceuticals, Inc.	-4.97%	-31.12%	-21.91%	15.48%	91.62%
Biontech Se	-1.42%	42.28%	6.01%	-49.15%	155.61%
Alnylam Pharmaceuticals, Inc.	-6.56%	-6.26%	22.36%	42.41%	102.91%
Vertex Pharmaceuticals Incorporated	-11.88%	-15.14%	-3.23%	81.51%	79.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cardiff Oncology Inc	NA	NA	NA	-0.99	-0.68	-0.38	NA	1.01
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cardiff Oncology Inc	Buy	$288.7M	258.68%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	91.62%	17.61	33.61%
Biontech Se	Buy	$27.3B	155.61%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	102.91%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	79.75%	32.84	-4.51%

About Cardiff Oncology

trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh

Organization	Cardiff Oncology
Employees	31
CEO	Dr. Mark Erlander Ph.D.
Industry	Health Services

Management People of Cardiff Oncology

Name	Title
Dr. Mark Erlander Ph.D.	CEO & Director
Mr. James E. Levine	Chief Financial Officer
Dr. Fairooz F. Kabbinavar FACP, M.D.	Chief Medical Officer
Dr. Tod Smeal Ph.D.	Chief Scientific Officer
Ms. Elizabeth Anderson	VP of Finance & Administration
Ms. Brigitte Lindsay	Senior Vice President of Finance
Mr. Charles Monahan R.Ph.	Senior Vice President of Regulatory Affairs

Important FAQs about investing in Cardiff Oncology from India :

What is Cardiff Oncology share price today?

Cardiff Oncology share price today stands at $4.26, Open: $4.40 ; Previous Close: $4.34 ; High: $4.63 ; Low: $4.24 ; 52 Week High: $6.42 ; 52 Week Low: $1.44. The stock opens at $4.40, after a previous close of $4.34. The stock reached a daily high of $4.63 and a low of $4.24, with a 52-week high of $6.42 and a 52-week low of $1.44.

Can Indians buy Cardiff Oncology shares?

Yes, Indians can invest in the Cardiff Oncology (CRDF) from India.

With INDmoney, you can buy Cardiff Oncology at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cardiff Oncology at zero transaction cost.

How can I buy Cardiff Oncology shares from India?

It is very easy to buy Cardiff Oncology from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cardiff Oncology be purchased?

Yes, you can buy fractional shares of Cardiff Oncology with INDmoney app.

What are the documents required to start investing in Cardiff Oncology stocks?

To start investing in Cardiff Oncology, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.